FDA Clears Pixclara as First Amino Acid PET Agent for Glioma Imaging
Telix Pharmaceuticals said on 14 September 2026 the FDA approved Pixclara, floretyrosine F 18, as the first amino acid PET imaging drug for glioma, helping distinguish recurrence from treatment related change.
What changed
Telix Pharmaceuticals announced on 14 September 2026 that the U.S. Food and Drug Administration approved its new drug application for Pixclara, floretyrosine F 18, an amino acid positron emission tomography agent for imaging gliomas.
Telix states Pixclara is the first FDA approved FET PET imaging drug for glioma. The indication covers adults and pediatric patients, addressing a need to differentiate recurrent or progressive glioma from treatment related change. Telix notes FET PET imaging is referenced in international clinical practice guidelines, including NCCN Guidelines.
The approval expands Telix’s precision medicine and theranostics portfolio alongside its existing radiopharmaceutical programs.
Why it matters
Brain tumor pathways stall when surgeons and oncologists cannot tell scar from active disease on conventional MRI alone. A labeled amino acid PET agent gives neuro oncology teams a reimbursable tool aligned with guideline language, which typically drives hospital formulary decisions faster than research only tracers.
For diagnostics investors, Pixclara reinforces Telix’s dual diagnostic and therapeutic thesis rather than a one asset oncology bet.
Who is affected
Neuro oncology centers must update imaging protocols, radiopharmacy handling, and prior authorization workflows for FET PET.
Payers will set coverage policies against NCCN cited evidence and post marketing utilization.
Competing PET developers in glioma need differentiated claims or combination strategies.
What to do next
Hospital pharmacy and nuclear medicine leads should begin Pixclara intake checklists now, including cyclotron or distributor supply contracts and pediatric dosing pathways referenced in the approved label materials Telix publishes.
What to watch
CMS coverage determinations, Telix launch timing for U.S. manufacturing and distribution partners, and whether guideline committees update mandatory imaging language beyond recommendation tier.
Sources
- Primary. Telix Pharmaceuticals, FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara (14 September 2026). Approval announcement, indication, and first in class FET PET claim.
- Secondary. RTTNews FDA calendar, FDA decision on TLX101-Px1 (14 September 2026). Confirms approval date alignment for Pixclara.